Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the filing of an IND application for a prophylactic breast cancer vaccine with the FDA. Developed in collaboration with a Cleveland Clinic research team, led by Dr. Vincent Tuohy, this innovative vaccine targets the protein alpha-lactalbumin, which re-emerges in breast cancer cases. Early animal studies demonstrate significant potential for preventing breast cancer. Funded by the U.S. Department of Defense, two Phase 1 clinical trials are planned. This vaccine aims to change breast cancer prevention approaches, particularly for women diagnosed with high-risk early-stage TNBC.
Anixa Biosciences, Inc. (NASDAQ: ANIX) will host a conference call on November 2, 2020, at 1:30 p.m. Pacific / 4:30 p.m. Eastern. CEO Dr. Amit Kumar will discuss key developments, including the upcoming Investigational New Drug (IND) application for a breast cancer vaccine in partnership with the Cleveland Clinic, progress on CAR-T therapy for ovarian cancer with Moffitt Cancer Center, and updates on COVID-19 therapy. Investors can join via phone at (877) 876-9174 (Conference ID: Anixa) or through a webcast on the company’s website.
Anixa Biosciences (NASDAQ: ANIX) announced that CEO Dr. Amit Kumar will present at the 2020 H.C. Wainwright Global Investment Conference from September 14-16, 2020. The presentation on September 16 at 10:00 a.m. ET will showcase the company's recent achievements in developing therapies against Covid-19 and its breast cancer vaccine and CAR-T based ovarian cancer programs. Interested parties can access the presentation here.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the identification of 26 new compounds targeting the main protease (Mpro) related to COVID-19, in collaboration with OntoChem. This follows the initial discovery of four compounds aimed at an endoribonuclease over four months. Anixa developed a library of over 8,000 chemicals, narrowing it down through machine learning to 317 candidates, ultimately leading to the 26 selected for synthesis and further testing. The company is preparing to file a U.S. provisional patent for these novel compounds.
Anixa Biosciences (NASDAQ: ANIX) announced progress in its prophylactic breast cancer vaccine, with plans to file an Investigational New Drug (IND) Application with the FDA by the end of Q3 2020. The vaccine, developed in collaboration with Cleveland Clinic, targets the alpha-lactalbumin protein, which is abnormally expressed in breast cancer. Despite challenges from the coronavirus pandemic, the development timeline remains on track. The bulk of the IND application is completed, with only the Chemistry, Manufacturing and Control (CMC) section pending.
Anixa Biosciences (NASDAQ: ANIX) announced a shift to a virtual format for its 2020 Annual Meeting of Stockholders due to COVID-19 safety concerns. The meeting is scheduled for August 13, 2020, at 10:00 a.m. PT, accessible through a live audio webcast. Shareholders can participate by logging in with the control number from their proxy materials. The company continues to develop cancer and infectious disease treatment programs, including a novel CAR-T technology and a COVID-19 therapeutic.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has received an Intention to Grant notice from the European Patent Office for its CAR-T cancer treatment technology, licensed from The Wistar Institute and developed at Moffitt Cancer Center. This patent, titled 'METHODS AND COMPOSITIONS FOR TREATING CANCER,' offers potential protection within the European Union for their innovative approach, particularly in treating ovarian cancer and other solid tumors. CEO Amit Kumar highlighted the significance of this intellectual property in advancing cancer therapies.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced on July 6, 2020, the completion of the initial drug discovery program in collaboration with OntoChem. They have identified a new compound and several analogs that might inhibit the main protease (Mpro) of a virus. The synthesized compounds are undergoing biological testing, with results expected soon. Additionally, a new in silico library has been created for further evaluation. The company aims to develop inexpensive oral medications for viral treatment, though it remains in the early developmental stages.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has announced a significant realignment of its business strategy to focus exclusively on developing therapeutics and vaccines for high-need patient populations. The company has suspended its Cchek™ liquid biopsy technology. Future efforts will center on cancer immunotherapy in collaboration with Moffitt Cancer Center and a breast cancer vaccine in partnership with Cleveland Clinic. Additionally, Anixa will continue its Covid-19 therapies with OntoChem. CEO Amit Kumar stated that the shift aims to maximize shareholder value amidst evolving market dynamics.